Comparison Overview

MENARINI Group

VS

Astellas Pharma

MENARINI Group

Via dei Sette Santi 1/3, Firenze, Italy, IT, 50131
Last Update: 2025-12-09
Between 750 and 799

The Menarini Group is a leading international pharmaceutical and diagnostics company, present in 140 countries worldwide, with a turnover of 4,37 Billion euro and more than 17,000 employees. With 9 centers for Research & Development, Menarini’s products are present in the most important therapeutic areas, including cardiology, oncology, gastroenterology, pneumology, infectious diseases, diabetes, and anti-inflammatory/analgesics. The Group’s pharmaceutical production is carried out in its 18 manufacturing plants, which produce over 609 million packets of product a year and distribute them to five continents. Menarini’s pharmaceutical production, in line with the highest quality standards, provides an ongoing contribution to the health of patients all over the world. For further information, please visit www.menarini.com For reading our Netiquette, please visit https://www.menarini.com/en-us/data-privacy/netiquette-of-menarini-group For reading our Privacy Notice for social networks users, please visit https://www.menarini.com/en-us/data-privacy/privacy-notice-for-social-network-users-of-menarini-group

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 10,572
Subsidiaries: 26
12-month incidents
0
Known data breaches
0
Attack type number
0

Astellas Pharma

2-5-1, Nihonbashi-Honcho, Chuo-Ku, Tokyo, JP, 103-8411
Last Update: 2025-12-09
Between 750 and 799

Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Visit our Global Astellas LinkedIn Community Guidelines to learn more about interacting with this page: https://www.astellas.com/en/global-linkedin-community-guidelines

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 11,951
Subsidiaries: 1
12-month incidents
0
Known data breaches
0
Attack type number
0

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/menarini.jpeg
MENARINI Group
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/astellaspharmainc.jpeg
Astellas Pharma
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
MENARINI Group
100%
Compliance Rate
0/4 Standards Verified
Astellas Pharma
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for MENARINI Group in 2025.

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Astellas Pharma in 2025.

Incident History — MENARINI Group (X = Date, Y = Severity)

MENARINI Group cyber incidents detection timeline including parent company and subsidiaries

Incident History — Astellas Pharma (X = Date, Y = Severity)

Astellas Pharma cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/menarini.jpeg
MENARINI Group
Incidents

No Incident

https://images.rankiteo.com/companyimages/astellaspharmainc.jpeg
Astellas Pharma
Incidents

No Incident

FAQ

Astellas Pharma company demonstrates a stronger AI Cybersecurity Score compared to MENARINI Group company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

Historically, Astellas Pharma company has disclosed a higher number of cyber incidents compared to MENARINI Group company.

In the current year, Astellas Pharma company and MENARINI Group company have not reported any cyber incidents.

Neither Astellas Pharma company nor MENARINI Group company has reported experiencing a ransomware attack publicly.

Neither Astellas Pharma company nor MENARINI Group company has reported experiencing a data breach publicly.

Neither Astellas Pharma company nor MENARINI Group company has reported experiencing targeted cyberattacks publicly.

Neither MENARINI Group company nor Astellas Pharma company has reported experiencing or disclosing vulnerabilities publicly.

Neither MENARINI Group nor Astellas Pharma holds any compliance certifications.

Neither company holds any compliance certifications.

MENARINI Group company has more subsidiaries worldwide compared to Astellas Pharma company.

Astellas Pharma company employs more people globally than MENARINI Group company, reflecting its scale as a Pharmaceutical Manufacturing.

Neither MENARINI Group nor Astellas Pharma holds SOC 2 Type 1 certification.

Neither MENARINI Group nor Astellas Pharma holds SOC 2 Type 2 certification.

Neither MENARINI Group nor Astellas Pharma holds ISO 27001 certification.

Neither MENARINI Group nor Astellas Pharma holds PCI DSS certification.

Neither MENARINI Group nor Astellas Pharma holds HIPAA certification.

Neither MENARINI Group nor Astellas Pharma holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

NXLog Agent before 6.11 can load a file specified by the OPENSSL_CONF environment variable.

Risk Information
cvss3
Base: 8.1
Severity: HIGH
CVSS:3.1/AV:L/AC:H/PR:N/UI:N/S:C/C:H/I:H/A:H
Description

uriparser through 0.9.9 allows unbounded recursion and stack consumption, as demonstrated by ParseMustBeSegmentNzNc with large input containing many commas.

Risk Information
cvss3
Base: 2.9
Severity: HIGH
CVSS:3.1/AV:L/AC:H/PR:N/UI:N/S:U/C:N/I:N/A:L
Description

A vulnerability was detected in Mayan EDMS up to 4.10.1. The affected element is an unknown function of the file /authentication/. The manipulation results in cross site scripting. The attack may be performed from remote. The exploit is now public and may be used. Upgrading to version 4.10.2 is sufficient to fix this issue. You should upgrade the affected component. The vendor confirms that this is "[f]ixed in version 4.10.2". Furthermore, that "[b]ackports for older versions in process and will be out as soon as their respective CI pipelines complete."

Risk Information
cvss2
Base: 5.0
Severity: LOW
AV:N/AC:L/Au:N/C:N/I:P/A:N
cvss3
Base: 4.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:U/C:N/I:L/A:N
cvss4
Base: 5.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:P/VC:N/VI:L/VA:N/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

MJML through 4.18.0 allows mj-include directory traversal to test file existence and (in the type="css" case) read files. NOTE: this issue exists because of an incomplete fix for CVE-2020-12827.

Risk Information
cvss3
Base: 4.5
Severity: HIGH
CVSS:3.1/AV:L/AC:H/PR:N/UI:N/S:C/C:L/I:N/A:L
Description

A half-blind Server Side Request Forgery (SSRF) vulnerability exists in kube-controller-manager when using the in-tree Portworx StorageClass. This vulnerability allows authorized users to leak arbitrary information from unprotected endpoints in the control plane’s host network (including link-local or loopback services).

Risk Information
cvss3
Base: 5.8
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:H/UI:N/S:C/C:H/I:N/A:N